Biohaven (BHVN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Definitive additional proxy materials filed, indicating updates or supplemental information for shareholders.
Voting matters and shareholder proposals
Proxy materials relate to matters requiring shareholder voting under Section 14(a) of the Securities Exchange Act.
Shareholder rights and capital structure
Filing includes information on securities classes and aggregate numbers relevant to voting and transactions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Biohaven
- Net loss narrowed on lower expenses; pivotal trial results for key programs expected in H2 2026.BHVN
Q2 2026 - Net loss narrowed to $130.5 million as cash reserves exceeded $350 million, supporting clinical progress.BHVNQ1 2026
- Votes will be held on director elections, auditor ratification, and executive compensation.BHVNProxy Filing
- Director elections, auditor ratification, and Say-on-Pay headline a year of strategic execution.BHVNProxy Filing
- First-in-class degraders, novel CNS and obesity therapies, and oncology assets advance toward pivotal trials in 2026.BHVN44th Annual J.P. Morgan Healthcare Conference presentation
- Net loss narrowed as cost optimization and capital raises support pivotal trials in 2026.BHVNQ4 2025
- Proxy covers director elections, auditor ratification, executive pay, and governance highlights.BHVNProxy Filing
- Q3 2025 saw a $173.4M net loss, major R&D cuts, and $263.8M in cash for near-term operations.BHVNQ3 2025
- Troriluzole slowed SCA progression by up to 70% over 3 years, with robust safety and efficacy.BHVNStudy Result